Federal Register / Vol. 75, No. 205 / Monday, October 25, 2010 / Notices 65489 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Respondents state epidemiologists form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Daily Novel and Pandemic Influenza A Virus State Case Status Summary Update ................. 57 1 15/60 

City Health Officers or Vital Statistics Registrars ........................................................................ 122 52 12/60 

Aggregate Hospitalization and Death Reporting Activity Weekly Report ................................... 56 52 10/60 

Monthly Respiratory & Enterovirus Surveillance Report: Excel format (electronic) .................... 25 12 15/60 

National Respiratory & Enteric Virus Surveillance System (NREVSS) ...................................... 90 52 10/60 

Enhanced Animal Rabies Surveillance (electronic) .................................................................... 52 52 3/60 

Rabies (paper) ............................................................................................................................. 3 12 15/60 

Possible Human Rabies Patient Info ........................................................................................... 50 1 15/60 

Waterborne Diseases Outbreak Form ......................................................................................... 57 1 20/60 

Cholera and other Vibrio illnesses .............................................................................................. 450 1 20/60 

Listeria ......................................................................................................................................... 53 1 30/60 

HABISS data entry form .............................................................................................................. 10 12 8 

HABISS monthly reporting form .................................................................................................. 10 12 30/60 

Babesiosis Case Report Form .................................................................................................... 54 12 10/60 

Brucellosis .................................................................................................................................... 56 2 20/60 

Petunia Gissendaner, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2010–26879 Filed 10–22–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30–Day–11–10EG] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

Audience Analysis for 

Biomonitoring—New—National Center 

for Environmental Health/Agency for 

Toxic Substances and Disease Registry 

(NCEH/ATSDR), Centers for Disease 

Control and Prevention (CDC). 

Background and Brief Description 

People’s exposure to environmental 

chemicals can be a risk to their health. 

Scientists at the CDC use biomonitoring, 

which is the measurement of 

environmental chemicals in human 

tissues and fluids, to assess such 

exposure. Biomonitoring findings, 

however, do not typically provide 

information on health risks and toxicity 

data often lag behind new 

biomonitoring data. The health effects 

on humans are, therefore, often 

uncertain or unknown, particularly, for 

many new or ‘‘emerging’’ chemicals. 

Nevertheless, communicating 

biomonitoring findings for those 

charged with this task is necessary, 

especially due to the growing media 

coverage and public concern about 

chemicals found in the human body. 

The demand for answers and decreasing 

patience with uncertainty characterizes 

the interpretation of such results. This 

poses enormous challenges to those 

tasked to communicate such findings to 

both scientific and non-scientific 

audiences without a biomonitoring 

background. 

The CDC is, therefore, interested in 

developing a framework for 

communicating health risk messages, 

particularly about emerging 

environmental chemicals, to the 

attentive public audience such as 

selected women who are pregnant or 

have very young children. The three 

environmental chemicals, Bisphenol A 

(BPA), phthalates, and mercury have 

been selected for this study. They are of 

particular interest to these selected 

women as the risks of exposure are 

higher for very young children because 

of their hand-to-mouth behaviors and 

direct oral (mouth) contact with 

materials containing these chemicals. 

Furthermore, young children eat and 

drink more per pound of body weight 

than adults. 

Focus groups will be conducted in 

different parts of the country with 

selected women. During phase one, 

eight exploratory focus groups will be 

conducted to develop messaging 

strategies and the results will be used in 

the development of preliminary 

messages about the emerging chemicals. 

The second phase will include six 

message testing focus groups to 

determine which messages are most 

attractive and compelling in terms of 

communicating health risk information 

about emerging chemicals. 

Participants will be recruited via 

standard focus group recruitment 

methods. Most will come from an 

existing database (or list) of potential 

participants maintained by the focus 

group facility. There is no cost to 

respondents other than their time. The 

total estimated annual burden hours are 

273. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of 

respondent Form name Number of respondents 

Responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Selected women for screening ....................... Recruitment Screener .................................... 252 1 5/60 


emcdonald on DSK2BSOYB1PROD with NOTICES
65490 Federal Register / Vol. 75, No. 205 / Monday, October 25, 2010 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of 

respondent Form name Number of respondents 

Responses 

per 

respondent 

Average 

burden per 

response 

(in hours) 

Selected women for exploratory focus groups Exploratory Focus Group Guide .................... 72 1 2 

Selected women for message testing focus 

groups.

Message Testing Focus Group Guide ........... 54 1 2 

Dated: October 19, 2010. 

Carol E. Walker, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2010–26878 Filed 10–22–10; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0542] 

Agency Information Collection 

Activities; Proposed Collection; 

Comment Request; Information 

Request Regarding Dissolvable 

Tobacco Products 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing an 

opportunity for public comment on the 

proposed collection of certain 

information by the Agency. Under the 

Paperwork Reduction Act of 1995 (the 

PRA), Federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information and to allow 60 days for 

public comment in response to the 

notice. This notice solicits comments on 

an information request regarding the use 

of dissolvable tobacco products. 

DATES: Submit either electronic or 

written comments on the collection of 

information by December 27, 2010. 

ADDRESSES: Submit electronic 

comments on the collection of 

information to http:// 

www.regulations.gov. Submit written 

comments on the collection of 

information to the Division of Dockets 

Management (HFA–305), Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1061, Rockville, MD 20852. All 

comments should be identified with the 

docket number found in brackets in the 

heading of this document. 

FOR FURTHER INFORMATION CONTACT: 

Jonna Capezzuto, Office of Information 

Management, Food and Drug 

Administration, 1350 Piccard Dr. PI50– 

400B, Rockville, MD 20850, 301–796– 

3794, 

Jonnalynn.Capezzuto@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: Under the 

PRA (44 U.S.C. 3501–3520), Federal 

agencies must obtain approval from the 

Office of Management and Budget 

(OMB) for each collection of 

information they conduct or sponsor. 

‘‘Collection of Information’’ is defined in 

44 U.S.C. 3502(3) and 5 CFR 1320.3(c) 

and includes Agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires Federal agencies 

to provide a 60-day notice in the 

Federal Register concerning each 

proposed collection of information 

before submitting the collection to OMB 

for approval. To comply with this 

requirement, FDA is publishing notice 

of the proposed collection of 

information set forth in this document. 

With respect to the following 

collection of information, FDA invites 

comments on these topics: (1) Whether 

the proposed collection of information 

is necessary for the proper performance 

of FDA’s functions, including whether 

the information will have practical 

utility; (2) the accuracy of FDA’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques, 

when appropriate, and other forms of 

information technology. 

Information Request Regarding 

Dissolvable Tobacco Products 

On June 22, 2009, the President 

signed the Family Smoking Prevention 

and Tobacco Control Act (Tobacco 

Control Act) (Pub. L. 111–31) into law. 

The Tobacco Control Act amended the 

Federal Food, Drug, and Cosmetic Act 

(FD&C Act) by adding a new chapter 

granting FDA important new authority 

to regulate the manufacture, marketing, 

and distribution of tobacco products to 

protect the public health generally and 

to reduce tobacco use by minors. 

Section 917 of the Tobacco Control 

Act required the Secretary of Health and 

Human Services (the Secretary) to 

establish a Tobacco Products Scientific 

Advisory Committee (TPSAC). Section 

907(f) of the Tobacco Control Act 

requires the TPSAC to submit a report 

and recommendations to the Secretary 

on the impact of the use of dissolvable 

tobacco products on the public health, 

including such use among children. To 

ensure a comprehensive review of this 

issue, FDA is requesting tobacco 

industry documents and information to 

support the work of TPSAC. Under 

section 907(f), TPSAC must submit its 

report and recommendations to the 

Secretary within 2 years of its 

formation, or March 23, 2012. 

In order to provide TPSAC with the 

information it needs to carry out its 

statutory obligation, FDA is requesting 

that tobacco companies submit 

information under section 904(b) of the 

Tobacco Control Act pertaining to 

documents and underlying scientific 

and financial information relating to 

research, and research findings, 

conducted, supported, or possessed by 

the manufacturer (or agents thereof) on 

a specified set of topics. For the 

purposes of this request, ‘‘research’’ may 

include, but is not limited to, focus 

groups, surveys, experimental clinical 

studies, post-marketing surveillance, 

toxicological and biochemical assays, 

taste panels, and assessments of the 

effectiveness of product marketing 

practices. Topics for which information 

relating to dissolvable tobacco products 

is requested are marketing research; 

marketing practices; effectiveness of 

marketing practices; and health, 

toxicological, behavioral, and 

physiological effects. FDA’s request for 

documents related to dissolvable 

tobacco products includes, but is not 

limited to products for research, 

investigational use, developmental 

studies, test marketing, and/or 

commercial marketing, and also to the 

components, parts, or accessories of 

such products. 


emcdonald on DSK2BSOYB1PROD with NOTICES